Hologic Downgraded by TheStreet to Hold (HOLX)
Hologic (NASDAQ:HOLX) was downgraded by equities researchers at TheStreet to a “hold” rating in a research report issued on Tuesday, Stock Ratings Network reports.
Shares of Hologic (NASDAQ:HOLX) traded up 0.68% during mid-day trading on Tuesday, hitting $20.65. 1,174,005 shares of the company’s stock traded hands. Hologic has a one year low of $18.46 and a one year high of $23.96. The stock has a 50-day moving average of $22.03 and a 200-day moving average of $21.30. The company’s market cap is $5.585 billion.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.37 by $0.01. The company had revenue of $626.10 million for the quarter, compared to the consensus estimate of $627.05 million. During the same quarter in the prior year, the company posted $0.35 earnings per share. The company’s quarterly revenue was up 33.2% on a year-over-year basis. Analysts expect that Hologic will post $1.48 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Raymond James downgraded shares of Hologic (NASDAQ:HOLX) from an “outperform” rating to a “market perform” rating in a research note to investors on Wednesday, September 11th. They now have a $23.00 price target on the stock. Separately, analysts at ISI Group raised their price target on shares of Hologic (NASDAQ:HOLX) from $22.50 to $25.00 in a research note to investors on Tuesday, August 6th. They now have a “buy” rating on the stock. Finally, analysts at Piper Jaffray Cos. downgraded shares of Hologic (NASDAQ:HOLX) from an “overweight” rating to a “neutral” rating in a research note to investors on Wednesday, July 17th. They now have a $21.00 price target on the stock, down previously from $27.00.
One research analyst has rated the stock with a sell rating, six have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $23.92.
In other Hologic news, CAO Robert H. Lavallee sold 2,500 shares of Hologic stock on the open market in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $20.33, for a total transaction of $50,825.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.